TY - JOUR
T1 - Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery
T2 - OPTIMISE II randomised clinical trial
AU - OPTIMISE II Trial Group
AU - Edwards, M.
AU - Edwards, Mark R.
AU - Pearse, Rupert M.
AU - Kahan, Brennan C.
AU - Hamborg, Thomas
AU - Priyadarshini, Garima
AU - MacDonald, Neil
AU - Mihaylova, Borislava
AU - Gordeev, Vladimir
AU - Assefa, Esubalew
AU - Dias, Priyanthi
AU - Thomson, Ann
AU - Grocott, Michael P.W.
AU - Mythen, Monty G.
AU - Gillies, Michael A.
AU - Sander, Michael
AU - Phan, Tuong
AU - Evered, Lisbeth
AU - Wijeysundera, Duminda N.
AU - McCluskey, Stuart A.
AU - Shaw, Andrew D.
AU - Weinstein, Mitchell
AU - Aldecoa, Cesar
AU - Ripollés-Melchor, Javier
AU - Hofer, Christoph K.
AU - Khudair, Hussein Abu
AU - Szczeklik, Wojciech
AU - Grigoras, Ioana
AU - Hajjar, Ludhmila A.
AU - Hewson, Russell
AU - Stefani, Luciana C.
AU - Treskatsch, Sascha
AU - Ganter, Michael T.
AU - van Vlymen, Janet
AU - Phull, Mandeep K.
AU - Lineburger, Eric B.
AU - Richebe, Philippe
AU - Chowdhury, Priyakam
AU - de Nadal, Míriam
AU - Ocón, Julia Martínez
AU - Sundar, Ashok
AU - Adkins, Gabrielle
AU - Abad-Motos, Ane
AU - Abad-Gurumeta, Alfredo
AU - Ristescu, Anca Irina
AU - Rusu, Daniel
AU - Martin, Timothy
AU - Joseph, Mareena
AU - Lakshminarasimhachar, Anand
AU - Royo, Marc
N1 - Publisher Copyright:
© 2024 BMJ Publishing Group. All rights reserved.
PY - 2024
Y1 - 2024
N2 - OBJECTIVES To evaluate the clinical effectiveness and safety of a perioperative algorithm for cardiac output-guided haemodynamic therapy in patients undergoing major gastrointestinal surgery. DESIGN Multicentre randomised controlled trial. SETTING Surgical services of 55 hospitals worldwide. PARTICIPANTS 2498 adults aged ≥65 years with an American Society of Anesthesiologists physical status classification of II or greater and undergoing major elective gastrointestinal surgery, recruited between January 2017 and September 2022. INTERVENTIONS Participants were assigned to minimally invasive cardiac output-guided intravenous fluid therapy with low dose inotrope infusion during and four hours after surgery, or to usual care without cardiac output monitoring. MAIN OUTCOME MEASURES The primary outcome was postoperative infection within 30 days of randomisation. Safety outcomes were acute cardiac events within 24 hours and 30 days. Secondary outcomes were acute kidney injury within 30 days and mortality within 180 days. RESULTS In 2498 patients (mean age 74 (standard deviation 6) years, 57% women), the primary outcome occurred in 289/1247 (23.2%) intervention patients and 283/1247 (22.7%) usual care patients (adjusted odds ratio 1.03 (95% confidence interval 0.84 to 1.25); P=0.81). Acute cardiac events within 24 hours occurred in 38/1250 (3.0%) intervention patients and 21/1247 (1.7%) usual care patients (adjusted odds ratio 1.82 (1.06 to 3.13); P=0.03). This difference was primarily due to an increased incidence of arrhythmias among intervention patients. Acute cardiac events within 30 days occurred in 85/1249 (6.8%) intervention patients and 79/1247 (6.3%) usual care patients (adjusted odds ratio 1.06 (0.77 to 1.47); P=0.71). Other secondary outcomes did not differ. CONCLUSIONS This clinical effectiveness trial in patients undergoing major elective gastrointestinal surgery did not provide evidence that cardiac output-guided intravenous fluid therapy with low dose inotrope infusion could reduce the incidence of postoperative infections. The intervention was associated with an increased incidence of acute cardiac events within 24 hours, in particular tachyarrhythmias. Based on these findings, the routine use of this treatment approach in unselected patients is not recommended.
AB - OBJECTIVES To evaluate the clinical effectiveness and safety of a perioperative algorithm for cardiac output-guided haemodynamic therapy in patients undergoing major gastrointestinal surgery. DESIGN Multicentre randomised controlled trial. SETTING Surgical services of 55 hospitals worldwide. PARTICIPANTS 2498 adults aged ≥65 years with an American Society of Anesthesiologists physical status classification of II or greater and undergoing major elective gastrointestinal surgery, recruited between January 2017 and September 2022. INTERVENTIONS Participants were assigned to minimally invasive cardiac output-guided intravenous fluid therapy with low dose inotrope infusion during and four hours after surgery, or to usual care without cardiac output monitoring. MAIN OUTCOME MEASURES The primary outcome was postoperative infection within 30 days of randomisation. Safety outcomes were acute cardiac events within 24 hours and 30 days. Secondary outcomes were acute kidney injury within 30 days and mortality within 180 days. RESULTS In 2498 patients (mean age 74 (standard deviation 6) years, 57% women), the primary outcome occurred in 289/1247 (23.2%) intervention patients and 283/1247 (22.7%) usual care patients (adjusted odds ratio 1.03 (95% confidence interval 0.84 to 1.25); P=0.81). Acute cardiac events within 24 hours occurred in 38/1250 (3.0%) intervention patients and 21/1247 (1.7%) usual care patients (adjusted odds ratio 1.82 (1.06 to 3.13); P=0.03). This difference was primarily due to an increased incidence of arrhythmias among intervention patients. Acute cardiac events within 30 days occurred in 85/1249 (6.8%) intervention patients and 79/1247 (6.3%) usual care patients (adjusted odds ratio 1.06 (0.77 to 1.47); P=0.71). Other secondary outcomes did not differ. CONCLUSIONS This clinical effectiveness trial in patients undergoing major elective gastrointestinal surgery did not provide evidence that cardiac output-guided intravenous fluid therapy with low dose inotrope infusion could reduce the incidence of postoperative infections. The intervention was associated with an increased incidence of acute cardiac events within 24 hours, in particular tachyarrhythmias. Based on these findings, the routine use of this treatment approach in unselected patients is not recommended.
UR - http://www.scopus.com/inward/record.url?scp=85214803741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85214803741&partnerID=8YFLogxK
U2 - 10.1136/bmj-2024-080439
DO - 10.1136/bmj-2024-080439
M3 - Article
C2 - 39626899
AN - SCOPUS:85214803741
SN - 0959-8146
JO - BMJ
JF - BMJ
M1 - e080439
ER -